Therapeutic anticoagulation is indicated for a variety of circumstances and conditions in
several fields of medicine to prevent or treat venous and arterial thromboembolism …

COVID-19 patients have a high incidence of thrombosis, and thromboembolic complications
are associated with severe COVID-19 and high mortality. COVID-19 disease is associated …

Oral anticoagulants are a mainstay for the prevention and treatment of arterial and venous
thrombosis. Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists (VKAs) …

Background Phase II randomized controlled trials (RCTs) on factor (F) XI inhibitors have
shown promising results but they were burdened by low statistical power for clinical …

Direct oral anticoagulants (DOACs) have largely replaced vitamin K antagonists, mostly
warfarin, for the main indications for oral anticoagulation, prevention and treatment of …

FXI (factor XI) and FXII (factor XII) have emerged as targets for new anticoagulants that have
the potential to be both more efficacious and safer than the currently available direct oral …

Thrombosis remains one of the leading causes of death in the world. The history of
anticoagulation has evolved considerably from non-specific drugs (ie, heparins and vitamin …

Anticoagulants are the mainstay for the prevention and treatment of thrombosis. However,
bleeding complications remain a primary concern. Recent advances in understanding the …

Anticoagulant drugs that are currently used to prevent and/or treat thrombosis have some
limitations that hinder their ability to meet specific clinical requirements. While these drugs …

Direct oral anticoagulants against activated factor X and thrombin were the last milestone in
thrombosis treatment. Step by step, they replaced antivitamin K and heparins in most of their …